Drug intelligence / Profile preview

VB-117

Development stage: Preclinical
Lead developer: Variant Bio
Modality: Antibody-Based Therapeutics

Overview

VB-117 is an investigational therapeutic antibody being developed by Variant Bio for the treatment of inflammatory diseases. Variant Bio utilizes a proprietary genomic platform to identify drug targets by analyzing genetic data from unique human populations worldwide. As of early 2026, the specific biological target of VB-117 remains confidential, though it is intended to modulate pathways associated with inflammation. The program is currently in the preclinical/discovery stage of development.

Beyond the preview

Go deeper on VB-117.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VB-117.

Explore the full profile